Search Results
Feb 10, 2026, 09:00 ET Circular Genomics Finalizes Exclusive IP Licenses with Leading Global Research Institutions to Advance circRNA Blood Test for Alzheimer's Disease
historically limited diagnostic innovation."These licenses represent a major strategic milestone for Circular Genomics," said Paul Sargeant, PhD., Chief Executive Officer of Circular Genomics. "Securing exclusive commercial rights from two of the most respected institutions in neurodegenerative
More news about: Circular Genomics
Feb 10, 2026, 09:00 ET Supreme Group Adds Science-First Creative Power with Acquisition of Broth
compelling creative execution."Broth was built on the belief that great healthcare marketing starts with respect for science," said Elizabeth Yi, PhD, one of the founders of Broth. "Joining Supreme Group allows us to scale our impact while staying true to our core principles as an agency that is rooted
More news about: Supreme Group
Feb 10, 2026, 09:00 ET DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
present data in an upcoming scientific publication."These results represent a major inflection point for Thykamine™," said Dr. Andre P. Boulet, PhD, Chief Executive Officer. "The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model,
More news about: Devonian Health Group Inc.
Feb 10, 2026, 08:31 ET First-Ever Standards and Ratings To Protect Teen Mental Health Online Launched Under the Leadership of The Mental Health Coalition
understanding the risks and supports available from their favorite platforms and for deciding where they will live their online lives." David S. Bickham PhD., Director of the Digital Wellness Lab, Boston Children's Hospital The Work AheadMHC calls on technology companies to participate
More news about: The Mental Health Coalition
Feb 10, 2026, 08:30 ET Embracing the Transformative Role of AI in Driving RWD Adoption, Upcoming Webinar Hosted by Xtalks
& Research Professor, Tufts Center for the Study of Drug Development; Mary Jo Lamberti, PhD, Director & Research Associate Professor, Tufts Center for the Study of Drug Development; and Aracelis Torres, PhD, MPH, Chief Data & Science Officer,
More news about: Xtalks
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates," said Tom Miller, PhD, Co-Founder and CEO of Iambic. "This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery
More news about: Market News Updates
Feb 10, 2026, 08:11 ET AI4Eyes Announces Expansion of Board of Directors
The Board of Directors includes Daniel Hofmann, BSc MBA, Dr. Tara Akhavan, PhD, Dr. John Hovanesian, and Ken McCracken CPA. Collectively, they bring deep experience across healthcare, medical technology, artificial intelligence,
More news about: AI4Eyes Medical Technologies Inc.
Feb 10, 2026, 08:09 ET Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma
Wnt inhibition."Tegavivint represents a novel approach to targeting one of the central biological drivers of osteosarcoma," said Rahul Aras, PhD, President and CEO of Iterion Therapeutics. "This first patient dosed marks an important clinical milestone for a program supported by extensive biological
More news about: Iterion Therapeutics
Feb 10, 2026, 08:00 ET Stellaromics Appoints Industry Veterans Stacie Weninger and Steve McPhail to Board of Directors
10, 2026 /PRNewswire/ -- Stellaromics, a pioneer in high-resolution 3D spatial multi-omics, today announced the appointment of Stacie Weninger, PhD, and Steve McPhail to its Board of Directors. These strategic appointments come at a pivotal time for the company as it scales its innovative Pyxa™ technology
More news about: Stellaromics
Feb 10, 2026, 08:00 ET Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
and are impressed by their thoughtful approach to integrating NeuLogiq digital endpoints into the S-898270 Phase 1 study protocol," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "In July, our team presented
More news about: Cumulus Neuroscience
Feb 10, 2026, 08:00 ET AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
affordability of medicines and better meeting the growing clinical needs.""We are delighted to collaborate with China Medical System," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "This strategic collaboration with CMS is a key step for Insilico Medicine in advancing
More news about: Insilico Medicine
Feb 10, 2026, 07:10 ET IRBM meldet Durchbruch bei der Entdeckung von Medikamenten gegen das Zika-Virus
Kandidaten vorzudringen."Diese Entdeckung ist ein wichtiger Meilenstein in der Entwicklung antiviraler Medikamente", sagte Carlo Toniatti, MD, PhD, Chief Scientific Officer am IRBM. "Durch den Einsatz modernster medizinischer Chemie und integrierter Screening-Technologien hat unser Team einen
More news about: IRBM S.p.A.
Feb 10, 2026, 07:00 ET New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis," said Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. "With both monthly and quarterly
More news about: Nektar Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
Leukemia in 2025. There are currently no approved CAR-T therapies for either indication.Investor contact:Claudio Santos, PhD[email protected] +34602672187Media
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics startet Phase-I/IIa-Studie zu einer CAR-T-Zelltherapie bei akuten Leukämien mit begrenzten Behandlungsoptionen
veröffentlicht. Für beide Indikationen gibt es derzeit keine zugelassenen CAR-T-Therapien.Kontakt für Investoren:Claudio Santos, PhD[email protected] +34602672187Medienkontakt:Gemma
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
Leukemia in 2025. There are currently no approved CAR-T therapies for either indication.Investor contact:Claudio Santos, PhD[email protected] +34602672187Media
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics inicia un ensayo clínico de fase I/IIa de una terapia con células CAR-T
2025. Actualmente no existen terapias CAR-T aprobadas para ninguna de las indicaciones.Contacto para inversores: Claudio Santos, PhD[email protected] +34602672187Contacto
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics lance un essai clinique de phase I/IIa évaluant une thérapie cellulaire CAR-T dans les leucémies aiguës pour lesquelles les options thérapeutiques sont limitées
actuellement aucune thérapie CAR-T approuvée pour l'une ou l'autre de ces indications.Contact pour les investisseurs :Claudio Santos, PhD[email protected] +34602672187Relations
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET IRBM Reports Breakthrough in Zika Virus Drug Discovery
preclinical candidate selection."This discovery marks an important milestone in antiviral drug development," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "By leveraging cutting-edge medicinal chemistry and integrated screening technologies, our team has delivered a
More news about: IRBM S.p.A.
Feb 10, 2026, 06:00 ET IRBM Reports Breakthrough in Zika Virus Drug Discovery
preclinical candidate selection."This discovery marks an important milestone in antiviral drug development," said Carlo Toniatti, MD, PhD, Chief Scientific Officer at IRBM. "By leveraging cutting-edge medicinal chemistry and integrated screening technologies, our team has delivered a
More news about: IRBM S.p.A.
Feb 10, 2026, 06:00 ET Ricerca IRBM: un passo avanti verso nuove terapie contro il virus Zika
candidato preclinico."Questa scoperta rappresenta un passo importante nello sviluppo di farmaci antivirali", ha dichiarato Carlo Toniatti, MD, PhD, Direttore Scientifico dell'IRBM. "Grazie alla stretta collaborazione tra gruppi di biologia, biochimica, screening, chimica medicinale e farmacologia,
More news about: IRBM S.p.A.
Feb 10, 2026, 02:00 ET Modern Meadow to Showcase INNOVERA™'s Cross‑Industry Applications at Lineapelle Milan 2026
Allbirds and ISA Next-Gen Materials marks a meaningful milestone for INNOVERA™ and we're proud to display it at Lineapelle," said David Williamson, PhD, CEO of Modern Meadow. "Our material's entry into footwear reinforces its ability to adapt across premium categories without compromising on performance,
More news about: Modern Meadow
Feb 10, 2026, 02:00 ET Modern Meadow presenterà le applicazioni intersettoriali di INNOVERA™ a Lineapelle Milano 2026
ISA Next-Gen Materials segna una tappa significativa per INNOVERA™ e siamo orgogliosi di presentarla a Lineapelle", ha dichiarato David Williamson, PhD, CEO di Modern Meadow. "L'ingresso del nostro materiale nel settore calzaturiero rafforza la sua capacità di adattarsi a categorie di fascia alta senza
More news about: Modern Meadow
Feb 09, 2026, 13:40 ET Allergy/Immunology Misinformation Often Goes Unchallenged in Social Media Landscape
Practice). "Patients are arriving in clinic already influenced by what they've seen on social media," said lead author Samira Jeimy, MD, PhD, FRCPC. "We found that the most engaging allergy/immunology social media content is often the least accurate, especially those around natural remedies
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 09, 2026, 11:33 ET WTWH Healthcare Announces Winners of 2025 Aspect Marketing & Advertising Awards
Marketing LeaderJonah Blumenthal, Chief Marketing Officer, TypoDuctions and DRIFTKarla Pena Rosa, PhD, LP, Psychologist and Certified Coach, Karla D. Pena Rosa, PhD, LLCLeah Lindgren, MHA, Executive Vice President of Consulting, Sales, and Marketing, HDGLori Beth Irvin,
More news about: WTWH Media